Deterioration of headache impact and health-related quality of life in migraine patients after cessation of preventive treatment with CGRP(−receptor) antibodies

BACKGROUND: Migraine preventive treatment with CGRP(−receptor) monoclonal antibodies (mAbs) has a positive effect on patients’ health-related quality of life (HRQoL). The German treatment guidelines recommend discontinuing successful treatment with CGRP(−receptor) mAbs after 6–12 months. We aimed to...

Descripción completa

Detalles Bibliográficos
Autores principales: Terhart, Maria, Mecklenburg, Jasper, Neeb, Lars, Overeem, Lucas Hendrik, Siebert, Anke, Steinicke, Maureen, Raffaelli, Bianca, Reuter, Uwe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8903665/
https://www.ncbi.nlm.nih.gov/pubmed/34972502
http://dx.doi.org/10.1186/s10194-021-01368-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8903665/
https://www.ncbi.nlm.nih.gov/pubmed/34972502
http://dx.doi.org/10.1186/s10194-021-01368-7

Ejemplares similares